Testing a novel nanofibre scaffold for utility in bone tissue regeneration.
Testing a novel nanofibre scaffold for utility in bone tissue regeneration.
复制标题
DOI：
10.1002/term.2740
复制
发表时间：
2018-10
影响因子：
3.3
通讯作者：
Cray J
中科院分区：
文献类型：
--
作者：
Howie RN;Durham E;Oakes B;Grey Z;Smith J;Campbell P;LaRue A;Steed M;Muise-Helmericks R;Cray J
许多变量会改变骨重建的过程，减少再生，包括创面床的大小和性质以及个体的健康状况。为了克服这些抑制因素，组织工程骨传导支架与各种生长因子配对已被应用于临床。然而，仍然存在许多局限性，例如骨形态发生蛋白2(BMP2)，可以导致猖獗的炎症、异位骨形成和移植失败。在这里，我们研究了纳米纤维支架(Talymed)促进BMP2生长因子诱导的骨愈合的能力，并与传统的可吸收胶原海绵(ACS)输送系统进行了比较。将155只成年野生型小鼠按时间、4周和8周分为16组，分别给予对照组、低、中、高剂量骨形态发生蛋白2。对颅骨进行显微CT、生物力学和组织学分析，以评估骨再生。与ACS/BMP2组合相比，在缺损处使用Talymed可以降低骨体积、骨形成率和ALP活性。有趣的是，尽管Talymed再生的骨较少，但在急性冠脉综合征组中，再生的骨的硬化值高于骨的硬度值。然而，8周后，不同支架之间的骨硬度差异并未被检测到。根据这些结果，我们发现纳米纤维支架在4周时产生了更好的骨再生质量，但由于缺乏全面的骨形成和对正常重建过程的抑制，不如目前临床标准的ACS/BMP2治疗有效。
Many variables serve to alter the process of bone remodeling and diminish regeneration including the size and nature of the wound bed and health status of the individual. To overcome these inhibitory factors, tissue engineered osteoconductive scaffolds paired with various growth factors have been utilized clinically. However, many limitations still remain, for example, bone morphogenetic protein 2 (BMP2), can lead to rampant inflammation, ectopic bone formation, and graft failure. Here we studied the ability for a nanofiber scaffold (Talymed) to accelerate BMP2 growth factor induced bone healing compared to the traditional absorbable collagen sponge (ACS) delivery system. 155 adult wild-type mice were arranged in 16 groups by time, 4 and 8 week, and treatment, ACS or Talymed, loaded with control, low, medium or high dosages of BMP2. Skulls were subjected to microCT, biomechanical, and histological analysis to assess bone regeneration. The use of Talymed within the defect site was found to decrease the bone volume, bone formation rate, and ALP activity compared to ACS/BMP2 combinations. Interestingly, though Talymed regenerated less bone, the regenerate was found to have a greater hardness value than that of bone within the ACS groups. However, the difference in bone hardness between scaffolds was not detectable by 8 weeks. Based on these results, we found that the nanofiber scaffold generated a better quality of bone regenerate at 4 weeks but, due to the lack of overall bone formation and the inhibition of normal remodeling processes, was not as efficacious as the current clinical standard ACS/BMP2 therapy.
登录
查看更多内容
影响因子：
3.6
作者：
Cooper GM;Mooney MP;Gosain AK;Campbell PG;Losee JE;Huard J
通讯作者：
Huard J
影响因子：
6.2
作者：
Dayer, Romain;Badoud, Isabelle;Ammann, Patrick
通讯作者：
Ammann, Patrick
影响因子：
14
作者：
Li, Bing;Yoshii, Toshitaka;Guelcher, Scott A.
通讯作者：
Guelcher, Scott A.
影响因子：
4.1
作者：
Herberg, Samuel;Kondrikova, Galina;Cray, James J.
通讯作者：
Cray, James J.
DOI：
10.1038/nrrheum.2014.164
发表时间：
2015-01
期刊：
Nature reviews. Rheumatology
影响因子：
--
作者：
通讯作者：
--